Cempra Pharmaceuticals completes Stage 1 clinical trials of CEM-101 macrolide Related StoriesBoehringer Ingelheim announces FDA acceptance of Praxbind McMaster research shows benefits of corticosteroid therapy for individuals with pneumoniaAmgen gets positive CHMP opinions for Kyprolis and BLINCYTO Cempra Pharmaceuticals today announced the effective completion of Phase 1 medical trials of its oral formulation of CEM-101, which showed good tolerability in those scholarly studies. The company also announced plans to post an IND to the FDA to begin with a Phase 1 study with the business’s intravenous formulation of CEM-101 in mid-2010. CEM-101 is usually a next-generation macrolide with potent activity against pneumococci, including macrolide – and quinolone-resistant strains.Almost three-quarters of all strokes take place in people older than 65 and the risk of experiencing a stroke more than doubles each decade following the age of 55. We’re facing an aging Babyboomer human population, an influx of 55-plus People in america, and treatment that’s less time-restrictive and in a position to repair the brain if a stroke destroys cells is urgently needed, said Alkon. How Bryostatin Functions Related StoriesStudy displays post-stroke lack of speech could be recoveredResearchers associate neuroimaging data with reading deficits in patients with left-sided strokePacemakers can identify AF and enable initiation of anticoagulation for stroke preventionStroke symptoms typically develop rapidly – – within seconds to mins – – and as oxygen turns into depleted in the mind tissue, cells die.